Skip to main content

2 Result(s)

within Mary Anne Dellva Remove this filter Diabetes Remove this filter

and

  1. Article

    Open Access

    Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension

    The PRONTO-T1D study, which evaluated the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes (T1D), met the primary endpoint of noninferiority of HbA1c change from ba...

    Juliana Bue-Valleskey, Leslie Klaff, Jang Ik Cho, Mary Anne Dellva… in Diabetes Therapy (2021)

    Download PDF (599 KB) View Article

  2. Article

    Open Access

    Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects

    Ultra rapid lispro (URLi) is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. The aims of this study were to demonstrate the bioequivalence (BE) of a...

    Helle Linnebjerg, Elizabeth Smith LaBell, Mary Anne Dellva… in Diabetes Therapy (2020)

    Download PDF (513 KB) View Article